The Big Volatility Lie
You're being lied to about volatility in 2015. And Mr. Market is the one doing the fibbing. Here's why...
View ArticleThe Big Volatility Lie
You're being lied to about volatility in 2015. And Mr. Market is the one doing the fibbing. Here's why...
View ArticleThe Calm Before the Storm? Here’s How to Prepare for What’s Coming
I think the stock market is lulling a lot of folks to sleep right now--and that's usually a sign a big move could be in the works. Could be up, could be down. It's impossible to predict which ways...
View ArticleExciting Offshore Competitor in Immunology With a Strong Platform Could Steal...
It’s my personal desire to find only companies that are sure to be winners. That’s why I’m so excited about this month’s recommendation. Using an exquisite yet complicated process, this company is...
View ArticleThe “Flash Crash” Case Gets Stranger… China’s True Intentions… the Fed’s Game...
Here are this week’s five recommended articles. You’ll see the Flash Crash case get stranger… China’s true intentions… the Fed’s game of chicken… why fintech companies are disrupting traditional banks…...
View ArticleSand in the Factory Gears
Where’s my recovery? Something much more worrisome than Greece. Plus… Best-case scenario: Stagnation. And wait till you hear the worst case…
View ArticleHow Inflation Affects Stocks
I’ve taken to reading Warren Buffett’s annual letters -- all 50 years -- from first to last. I figure I’ll read one a day. Whatever you think of Buffett the man, there is no denying the letters are a...
View ArticleHow a Government Screw-up Can Hand You Double-digit Gains
Your data isn't just limited to your hard drive. It's floating around everywhere--through distant servers and "the cloud". So it's not a question of if your data is stolen... but when. And private...
View ArticleTrade Alert: Capture $320 From the Tight Rental Market
We're going to take a look at a homebuilder that should do very well as demand for homes picks up. In fact, we should be able to capture an instant payment of $320 from the strength in this home...
View ArticleFlash Sell! Take 110% Profit on This Glaucoma Developer Now!
Baron Rothschild is credited with saying, “Buy when there's blood in the streets.” In biotech investing, it's more like, “Buy when there's blood after a clinical trial.” Let’s take the opportunity to...
View ArticleNew Buy Triggered: Disruption and Deflation
Stand to double your money in a disrupted industry…
View ArticleLosing Faith and Getting Real
Faith in the Fed starting to crack. Plus... Awaiting the next financial crisis: The big takeaway from yesterday’s AIG court ruling
View ArticleYour Secret Obsession Can Make You Fast, Double-digit Gains
Doughnut sales from quick service restaurants, like Krispy Kreme and Dunkin' Donuts, are up for the third straight year, after several years in decline, the Washington Post reports. Doughnut giant...
View ArticleBreaking Clinical Trial News: You’re up 86% in a Biotech That Has Started to...
We've been waiting for Phase 3 trial results, and early this a.m., this biotech company released them.
View ArticleFrequently Asked Questions Answered
Here are thirty-five of the most frequently asked questions answered. I hope you find them useful as you invest. We will be updating these on a monthly basis.
View ArticleMidweek Briefing — Follow the Rigs to Oil’s Next Bull Market
On Dec. 17, 2014, I offered a prediction about where U.S. oil production would be by the end of the second quarter 2015. At the time I made the prediction, I was definitely in a very small minority of...
View ArticleThe Next Financial Crisis
If liquidity in the Treasury market is “worse than you know”, it’s worse still in another sector: A $14 trillion time bomb, closer to detonation
View ArticleSTORM Alert: Update, Plus a Sell
U.S. markets are riding a rollercoaster today, with the latest statement from the Fed on everyone's radar. Because of the flux in stocks today, I'm holding onto your watch list until tomorrow. I want...
View ArticleSTORM Alert: Update, Plus a Sell
U.S. markets are riding a rollercoaster today, with the latest statement from the Fed on everyone's radar. Because of the flux in stocks today, I'm holding onto your watch list until tomorrow. I want...
View ArticleMidweek Update: Developments at Our Cancer Developers
In April, I recommended picking up shares of this biotech company. We've seen the FDA become a more amenable beast, willing to allow drugs approval if a company can show that a subgroup of patients can...
View Article